<?xml version="1.0" encoding="utf-8" ?><rss version="2.0"><channel><title>Bing: Database Complex System</title><link>http://www.bing.com:80/search?q=Database+Complex+System</link><description>Search results</description><image><url>http://www.bing.com:80/s/a/rsslogo.gif</url><title>Database Complex System</title><link>http://www.bing.com:80/search?q=Database+Complex+System</link></image><copyright>Copyright © 2026 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Bing results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.</copyright><item><title>bioRxiv</title><link>https://www.biorxiv.org/content/biorxiv/early/2026/06/24/2026.06.24.734237/DC1/embed/media-1.docx?download=true</link><description>All participants provided written informed consent prior to sample collection, and all procedures involving human biological material were conducted in accordance with the Human Tissue Act 2004 (Human Tissue Authority). All procedures involving human biological material were conducted in accordance with relevant institutional guidelines and regulations and complied with the principles outlined ...</description><pubDate>Thu, 25 Jun 2026 07:55:00 GMT</pubDate></item><item><title>asset.jnjwithme.com</title><link>https://asset.jnjwithme.com/document/erleada-sample-letter-of-appeal.docx?v=20260627</link><description>Clinical data from Precision Point Specialty (PPS) Analytics from community urology practices were linked with administrative claims data from the Komodo Research Database (08/05/2022 in the darolutamide without docetaxel cohort to 06/30/2025, and 12/16/2018 in the enzalutamide cohort and 09/17/2018 in the abiraterone acetate cohort to 12/31 ...</description><pubDate>Sat, 27 Jun 2026 07:03:00 GMT</pubDate></item><item><title>www.medrxiv.org</title><link>https://www.medrxiv.org/content/medrxiv/early/2026/06/24/2026.06.22.26355869/DC1/embed/media-1.docx?download=true</link><description>Figure S1. OncoKB[28,29]Annotation of Clinical Actionability by Genetic Ancestry: The clinical actionability of single nucleotide, copy number, structural, and atypical variants were annotated using the OncoKB database. Level 1 represents a biomarker for standard of care treatment (high actionability), while Level 4 represents a hypothetical biomarker (low actionability).</description><pubDate>Thu, 25 Jun 2026 06:01:00 GMT</pubDate></item></channel></rss>